Učitavanje...
Novel Therapies in Multiple Myeloma for Newly Diagnosed Non-Transplant Candidates
In the 21(st) Century, melphalan-prednisone can no longer be regarded as the standard treatment of multiple myeloma patients not eligible for high-dose melphalan followed by autologous stem cell transplantation. The introduction of thalidomide, lenalidomide and bortezomib has improved the arsenal of...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2009
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2818857/ https://ncbi.nlm.nih.gov/pubmed/20010166 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0b013e3181c60f08 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|